The Carboprost Tromethamine market is projected to register a CAGR of 3.9% during the forecast period (2022 - 2027).
With the rise of COVID 19, there has been a rise in other complications that arise along with the infection. As per the American College of Obstetricians and Gynecologists' COVID-19 FAQs for Obstetrician - Gynecologists, Obstetrics updated in July 2020, Carboprost Tromethamine is contraindicated for pregnant women with asthma or other respiratory issues since the drug is associated with the occurrence of bronchospasms. The article mentions that even though there is no specific data relating the COVID-19 infection to the use of Carboprost Tromethamine, the indications of COVID-19, especially viral pneumonia, could be of concern. Since COVID-19 increases the risk of thrombosis given the hypercoagulative state of pregnancy, the use of Carboprost Tromethamine should be thoroughly consulted before the application. An article presented in the journal Anesthesia and Analgesia in March 2020, reported a case of bronchospasm in postpartum hemorrhage treatment with Carboprost Tromethamine. The patient was tested positive for COVID-19, which could have influenced the treatment of postpartum hemorrhage. With the number of COVID cases diminishing, the adverse effects of the virus on postpartum hemorrhage treatment is expected to reduce, thereby boosting the growth of the studied market in the forecast period.
Postpartum hemorrhage is the leading cause of maternal death worldwide. According to the 2020 article on Maternal Morbidity and Mortality from National Institute of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development department of the US Department of Health and Human Services, bleeding (also known as hemorrhage) is one of the major causes of the maternal morbidity and mortality. The number of postpartum cases throughout the world has also been rising. As per an article presented in the Commonwealth Fund in December 2020, severe postpartum bleeding accounts for about 11.1% of the maternal mortality in the United States. Another article published in the Nursing Reports journal in December 2020, the increasing rate of atonic postpartum hemorrhage was confirmed in the Saudi Arabia. According to the article on Abortion by the World Health Organization published in November 2021, around 73 million induced abortions take place worldwide each year. WHO has included the comprehensive abortion care in the list of essential health care services 2020. The rising cases of postpartum hemorrhage and the increase in the number of abortions require proper medications for the treatment and prevention of maternal mortality. This increase is expected to boost the growth of the Carboprost Tromethamine market in the forecast period.
The Postpartum Hemorrhage is a major cause of the maternal mortality and morbidity. As per the World Health Organisation’s data on Maternal, Newborn, Child and Adolescent Health and Ageing, in 2021, India had the largest number of births in the world, with around 24,016.020 thousands, followed by China with 15,918.889 thousands. The large birth rate also results in a rise in the number of postpartum hemorrhage cases. An article published in the BMC journal of Reproductive Health in March 2022 estimated that postpartum mortality is one of the leading causes of maternal mortality in developing countries, accounting to around 25 - 43% of total maternal death. The article also indicated that the magnitude of postpartum hemorrhage among post-natal mothers in Ethiopia is moderately high. The huge rise in the postpartum hemorrhage cases in turn affects the treatment and aids in the sale of the carboprost tromethamine injections.
An article published in the Tropical Journal of Pharmaceutical Research in May 2020 studied the effects of Carboprost tromethamine in the treatment of caesarean associated postpartum hemorrhage and concluded that Carboprost Tromethamine prevents postpartum hemorrhage after caesarean section. The study also implied that it effectively reduces bleeding and promotes uterine involution, without obvious adverse reactions.Recent researches have also focused on the combination therapy of Carboprost Tromethamine with other drugs on their action on postpartum hemorrhage. An article published in the journal, Medicine in July 2021, examined the efficacy of Carboprost Tromethamine combined with the Leonurus Japonicus Injection for the prevention of postpartum hemorrhage in high-risk pregnant women. The study suggested that the prophylactic use of Leonurus Japonicus Injection in combination with Carboprost Tromethamine may have a good effect on the prevention of postpartum hemorrhage after delivery. There is a large importance placed on the research of using Carboprost Tromethamine and the magnitude of the research work being done on further therapy is subtantial. These factors are expected to have a significant impact on the growth of the Carboprost Tromethamine market in the upcoming period.
According to the World Health Organisation, the number of births in the United States for the year 2021 is 3,985.712 thousands. The high number of child births is associated with the increasing postpartum hemorrhage cases. The number of live births is projected to reach around 4,124.888 thousands by 2050. The National Instiute for Children’s Health Quality in April 2022 revealed that around 3% of the deliveries in the United States reported cases of postpartum hemorrhage. The cases accounted for more than 100,000 births per year. The above source also showed that the hospitals may be able to prevent up to 70 percent of hemorrhage relate obstetric deaths. Proper treatment strategies could help reduce the maternal mortality in the US. Carboprost Tromethamine, is established to counteract the effects of postpartum hemorrhage in pregnant women. Thus, the market for the Carboprost Tromethamne is expected to grow in the United States region in the forecast period.
As per the United Health Foundation America’s Health Rankings for the year 2021, the United States had around 30.6% of unintended pregnancies over the year. The increased awareness and advanced treatment rates account for the larger disposition of Carboprost Tromethamine in the North American region. The increase in the prescription rates of the innovative medicine is expected to drive the demand for the Carboprost Tromethamine market in the North American region. An article published in the IOSR Journal of Dental and Medical Sciences in June 2020 demonstrated that Carboprost tromethamine was reported to be 84 - 96% effective in the treatment of persistent hemorrhage due to uterine atony, and may avoid the need for surgical intervention. Increase in research and development in the clinical stage companies in the novel treatments for the postpartum hemorrhage is predicted to boost the growth of Carboprost Tromethamine market in the region. There also has been an increase in the number of cases in the Asia Pacific, owing to rapid industrialization and improved awareness among the population. The Asia Pacific region, is expected to be fastest growing market due to larger consumer base and increasing approval of Carboprost Tromethamine.
The Carboprost Tromethamine market is fragmented competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer, ChemScene, Universal Biologicals, Woodward Pharma , Amneal Pharmaceuticals LLP, Dr. Reddy's Laboratories Ltd., Merck KGaA, Bio-Techne, SimSon Pharma Limited and others.
This product will be delivered within 2 business days.
With the rise of COVID 19, there has been a rise in other complications that arise along with the infection. As per the American College of Obstetricians and Gynecologists' COVID-19 FAQs for Obstetrician - Gynecologists, Obstetrics updated in July 2020, Carboprost Tromethamine is contraindicated for pregnant women with asthma or other respiratory issues since the drug is associated with the occurrence of bronchospasms. The article mentions that even though there is no specific data relating the COVID-19 infection to the use of Carboprost Tromethamine, the indications of COVID-19, especially viral pneumonia, could be of concern. Since COVID-19 increases the risk of thrombosis given the hypercoagulative state of pregnancy, the use of Carboprost Tromethamine should be thoroughly consulted before the application. An article presented in the journal Anesthesia and Analgesia in March 2020, reported a case of bronchospasm in postpartum hemorrhage treatment with Carboprost Tromethamine. The patient was tested positive for COVID-19, which could have influenced the treatment of postpartum hemorrhage. With the number of COVID cases diminishing, the adverse effects of the virus on postpartum hemorrhage treatment is expected to reduce, thereby boosting the growth of the studied market in the forecast period.
Postpartum hemorrhage is the leading cause of maternal death worldwide. According to the 2020 article on Maternal Morbidity and Mortality from National Institute of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development department of the US Department of Health and Human Services, bleeding (also known as hemorrhage) is one of the major causes of the maternal morbidity and mortality. The number of postpartum cases throughout the world has also been rising. As per an article presented in the Commonwealth Fund in December 2020, severe postpartum bleeding accounts for about 11.1% of the maternal mortality in the United States. Another article published in the Nursing Reports journal in December 2020, the increasing rate of atonic postpartum hemorrhage was confirmed in the Saudi Arabia. According to the article on Abortion by the World Health Organization published in November 2021, around 73 million induced abortions take place worldwide each year. WHO has included the comprehensive abortion care in the list of essential health care services 2020. The rising cases of postpartum hemorrhage and the increase in the number of abortions require proper medications for the treatment and prevention of maternal mortality. This increase is expected to boost the growth of the Carboprost Tromethamine market in the forecast period.
Key Market Trends
The Postpartum Hemorrhage Treatment Segment is Expected to Hold a Major Market Share in the Carboprost Tromethamine Market.
The Postpartum Hemorrhage is a major cause of the maternal mortality and morbidity. As per the World Health Organisation’s data on Maternal, Newborn, Child and Adolescent Health and Ageing, in 2021, India had the largest number of births in the world, with around 24,016.020 thousands, followed by China with 15,918.889 thousands. The large birth rate also results in a rise in the number of postpartum hemorrhage cases. An article published in the BMC journal of Reproductive Health in March 2022 estimated that postpartum mortality is one of the leading causes of maternal mortality in developing countries, accounting to around 25 - 43% of total maternal death. The article also indicated that the magnitude of postpartum hemorrhage among post-natal mothers in Ethiopia is moderately high. The huge rise in the postpartum hemorrhage cases in turn affects the treatment and aids in the sale of the carboprost tromethamine injections.
An article published in the Tropical Journal of Pharmaceutical Research in May 2020 studied the effects of Carboprost tromethamine in the treatment of caesarean associated postpartum hemorrhage and concluded that Carboprost Tromethamine prevents postpartum hemorrhage after caesarean section. The study also implied that it effectively reduces bleeding and promotes uterine involution, without obvious adverse reactions.Recent researches have also focused on the combination therapy of Carboprost Tromethamine with other drugs on their action on postpartum hemorrhage. An article published in the journal, Medicine in July 2021, examined the efficacy of Carboprost Tromethamine combined with the Leonurus Japonicus Injection for the prevention of postpartum hemorrhage in high-risk pregnant women. The study suggested that the prophylactic use of Leonurus Japonicus Injection in combination with Carboprost Tromethamine may have a good effect on the prevention of postpartum hemorrhage after delivery. There is a large importance placed on the research of using Carboprost Tromethamine and the magnitude of the research work being done on further therapy is subtantial. These factors are expected to have a significant impact on the growth of the Carboprost Tromethamine market in the upcoming period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period (2022 - 2027).
According to the World Health Organisation, the number of births in the United States for the year 2021 is 3,985.712 thousands. The high number of child births is associated with the increasing postpartum hemorrhage cases. The number of live births is projected to reach around 4,124.888 thousands by 2050. The National Instiute for Children’s Health Quality in April 2022 revealed that around 3% of the deliveries in the United States reported cases of postpartum hemorrhage. The cases accounted for more than 100,000 births per year. The above source also showed that the hospitals may be able to prevent up to 70 percent of hemorrhage relate obstetric deaths. Proper treatment strategies could help reduce the maternal mortality in the US. Carboprost Tromethamine, is established to counteract the effects of postpartum hemorrhage in pregnant women. Thus, the market for the Carboprost Tromethamne is expected to grow in the United States region in the forecast period.
As per the United Health Foundation America’s Health Rankings for the year 2021, the United States had around 30.6% of unintended pregnancies over the year. The increased awareness and advanced treatment rates account for the larger disposition of Carboprost Tromethamine in the North American region. The increase in the prescription rates of the innovative medicine is expected to drive the demand for the Carboprost Tromethamine market in the North American region. An article published in the IOSR Journal of Dental and Medical Sciences in June 2020 demonstrated that Carboprost tromethamine was reported to be 84 - 96% effective in the treatment of persistent hemorrhage due to uterine atony, and may avoid the need for surgical intervention. Increase in research and development in the clinical stage companies in the novel treatments for the postpartum hemorrhage is predicted to boost the growth of Carboprost Tromethamine market in the region. There also has been an increase in the number of cases in the Asia Pacific, owing to rapid industrialization and improved awareness among the population. The Asia Pacific region, is expected to be fastest growing market due to larger consumer base and increasing approval of Carboprost Tromethamine.
Competitive Landscape
The Carboprost Tromethamine market is fragmented competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer, ChemScene, Universal Biologicals, Woodward Pharma , Amneal Pharmaceuticals LLP, Dr. Reddy's Laboratories Ltd., Merck KGaA, Bio-Techne, SimSon Pharma Limited and others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amneal Pharmaceuticals LLP
- ChemScene
- Dr. Reddy's Laboratories Ltd.
- Merck KGaA
- Pfizer
- Universal Biologicals
- Woodward Pharma
Methodology
LOADING...
